{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:40:10Z","timestamp":1787899210682,"version":"build-2784847793"},"reference-count":40,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/M001555\/1"],"award-info":[{"award-number":["BB\/M001555\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/M021629\/1"],"award-info":[{"award-number":["BB\/M021629\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["13\/0004659"],"award-info":[{"award-number":["13\/0004659"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Fibroblast growth factor 21 (FGF21) secretion has been shown to respond directly to carbohydrate consumption, with glucose, fructose, and sucrose all reported to increase plasma levels of FGF21 in rodents and humans. However, carbohydrate consumption also results in secretion of insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Circulating glucose, insulin, total and bioactive FGF21, and fibroblast activation protein were measured in adults with and without type 2 diabetes (T2D) following an oral glucose tolerance test (OGTT), and under a series of insulin and glucose clamp conditions and following high-fat diet in healthy adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Circulating total and bioactive FGF21 levels responded acutely to OGTT, and their ratio was attenuated in T2D patients with reduced postprandial insulin response. The clamp studies revealed that insulin but not glucose accounts for the postprandial rise in FGF21. Finally, there was an attenuated rise in FGF21 in response to a high-fat dietary intervention that is known to alter insulin-stimulated substrate utilization in metabolically active tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Insulin rather than glucose per se increases total and bioactive FGF21 in the postprandial period in adult humans. Understanding the impact of T2D on bioactive FGF21 will have a significant effect upon the efficacy of therapeutic agents designed to target the FGF21 pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2017-01257","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T14:09:12Z","timestamp":1501855752000},"page":"3806-3813","source":"Crossref","is-referenced-by-count":59,"title":["FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans"],"prefix":"10.1210","volume":"102","author":[{"given":"Ricardo J","family":"Samms","sequence":"first","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Queen\u2019s Medical Centre, Nottingham, United Kingdom"},{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo E","family":"Lewis","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Queen\u2019s Medical Centre, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Norton","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis B","family":"Stephens","sequence":"additional","affiliation":[{"name":"Department of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Department of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Butterfield","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis P","family":"Smith","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C","family":"Cheng","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James W","family":"Perfield","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Adams","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J P","family":"Ebling","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Queen\u2019s Medical Centre, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Tsintzas","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Queen\u2019s Medical Centre, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"issue":"3","key":"2020071619394594300_B1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"issue":"6","key":"2020071619394594300_B2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tem.2014.03.001","article-title":"FGF21-based pharmacotherapy--potential utility for metabolic disorders","volume":"25","author":"Gimeno","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2020071619394594300_B3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"2020071619394594300_B4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jcp.21675","article-title":"Different roles of N- and C- termini in the functional activity of FGF21","volume":"219","author":"Micanovic","year":"2009","journal-title":"J Cell Physiol"},{"issue":"4","key":"2020071619394594300_B5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"Suzuki","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2020071619394594300_B6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2014.09.008","article-title":"Fructose ingestion acutely stimulates circulating FGF21 levels in humans","volume":"4","author":"Dushay","year":"2014","journal-title":"Mol Metab"},{"issue":"12","key":"2020071619394594300_B7","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"2020071619394594300_B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fendo.2013.00194","article-title":"Stressed liver and muscle call on adipocytes with FGF21","volume":"4","author":"Luo","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2020071619394594300_B9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cmet.2012.11.001","article-title":"Circulating fibroblast growth factors as metabolic regulators--a critical appraisal","volume":"16","author":"Angelin","year":"2012","journal-title":"Cell Metab"},{"key":"2020071619394594300_B10","first-page":"65","article-title":"Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus","volume":"116(1)","author":"Chen","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"2020071619394594300_B11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"2020071619394594300_B12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes"},{"issue":"1","key":"2020071619394594300_B13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmet.2008.05.006","article-title":"Inhibition of growth hormone signaling by the fasting-induced hormone FGF21","volume":"8","author":"Inagaki","year":"2008","journal-title":"Cell Metab"},{"issue":"2","key":"2020071619394594300_B14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"2020071619394594300_B15","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1172\/JCI83349","article-title":"FGF21 and the late adaptive response to starvation in humans","volume":"125","author":"Fazeli","year":"2015","journal-title":"J Clin Invest"},{"issue":"2","key":"2020071619394594300_B16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","article-title":"FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver","volume":"23","author":"von Holstein-Rathlou","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"2020071619394594300_B17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"2020071619394594300_B18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molmet.2016.11.001","article-title":"Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates","volume":"6","author":"Lundsgaard","year":"2016","journal-title":"Mol Metab"},{"issue":"1","key":"2020071619394594300_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","article-title":"A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism","volume":"6","author":"Fisher","year":"2016","journal-title":"Mol Metab"},{"issue":"5","key":"2020071619394594300_B20","doi-asserted-by":"crossref","first-page":"E1105","DOI":"10.1152\/ajpendo.00348.2009","article-title":"Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects","volume":"297","author":"Xu","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"2020071619394594300_B21","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/ac303203y","article-title":"Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities","volume":"85","author":"Hager","year":"2013","journal-title":"Anal Chem"},{"issue":"5","key":"2020071619394594300_B22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem J"},{"key":"2020071619394594300_B23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs","volume":"4","author":"Keane","year":"2013","journal-title":"FEBS Open Bio"},{"issue":"5","key":"2020071619394594300_B24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"Pt 10","key":"2020071619394594300_B25","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1113\/jphysiol.2009.169078","article-title":"Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men","volume":"587","author":"Br\u00f8ns","year":"2009","journal-title":"J Physiol"},{"issue":"1","key":"2020071619394594300_B26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1210\/jc.2006-1592","article-title":"High-fat\/low-carbohydrate diet reduces insulin-stimulated carbohydrate oxidation but stimulates nonoxidative glucose disposal in humans: an important role for skeletal muscle pyruvate dehydrogenase kinase 4","volume":"92","author":"Chokkalingam","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2020071619394594300_B27","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1210\/en.2009-0466","article-title":"Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction","volume":"150","author":"S\u00e1nchez","year":"2009","journal-title":"Endocrinology"},{"issue":"17","key":"2020071619394594300_B28","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.febslet.2009.07.053","article-title":"Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes","volume":"583","author":"Iizuka","year":"2009","journal-title":"FEBS Lett"},{"issue":"8","key":"2020071619394594300_B29","doi-asserted-by":"crossref","first-page":"e22976","DOI":"10.1371\/journal.pone.0022976","article-title":"Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor","volume":"6","author":"Uebanso","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"2020071619394594300_B30","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J Biol Chem"},{"issue":"3","key":"2020071619394594300_B31","doi-asserted-by":"crossref","first-page":"e0151269","DOI":"10.1371\/journal.pone.0151269","article-title":"Human FGF-21 is a substrate of fibroblast activation protein","volume":"11","author":"Coppage","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"2020071619394594300_B32","doi-asserted-by":"crossref","first-page":"e49977","DOI":"10.1371\/journal.pone.0049977","article-title":"FGF21 requires \u03b2klotho to act in vivo","volume":"7","author":"Adams","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2020071619394594300_B33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab"},{"issue":"4","key":"2020071619394594300_B34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cell Metab"},{"issue":"2","key":"2020071619394594300_B35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2016.12.004","article-title":"FGF21 is an exocrine pancreas secretagogue","volume":"25","author":"Coate","year":"2017","journal-title":"Cell Metab"},{"issue":"6","key":"2020071619394594300_B36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr Rev"},{"issue":"6","key":"2020071619394594300_B37","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"issue":"10","key":"2020071619394594300_B38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","article-title":"Fibroblast activation protein (FAP) as a novel metabolic target","volume":"5","author":"S\u00e1nchez-Garrido","year":"2016","journal-title":"Mol Metab"},{"issue":"9","key":"2020071619394594300_B39","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/13543784.16.9.1459","article-title":"Talabostat","volume":"16","author":"Cunningham","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"2020071619394594300_B40","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2012.03.107","article-title":"Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP\/prolyl oligopeptidase (PREP)-selectivity","volume":"22","author":"Ryabtsova","year":"2012","journal-title":"Bioorg Med Chem Lett"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/10\/3806\/24572350\/jc.2017-01257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/10\/3806\/24572350\/jc.2017-01257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:39:26Z","timestamp":1594946366000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/10\/3806\/4064265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01257","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,8,4]]}}}